Glaukos beats Q2 sales estimates, raises 2025 guidance

Glaukos

30/07/2025 21:14

Overview

Glaukos Q2 2025 net sales rise 30% yr/yr, beating analyst expectations

The ophthalmic medical technology company raises 2025 net sales guidance to $480 mln-$486 mln

Q2 adjusted net loss beats analyst estimates

Outlook

Glaukos raises 2025 sales guidance to $480 mln-$486 mln

Glaukos focuses on advancing novel eye disease technologies

Result Drivers

GROWTH IN GLAUCOMA SALES - Record net sales in glaucoma segment, with U.S. sales up 45% yr/yr

STRATEGIC EXECUTION - CEO attributes growth to successful execution of strategic plans

PIPELINE ADVANCEMENT - Continued advancement of novel, dropless platform technologies

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Sales
Beat
$124.10 mln
$115.50 mln (14 Analysts)
Q2 EPS
-$0.34
Q2 Adjusted Net Income
Beat
-$13.60 mln
-$15.10 mln (12 Analysts)
Q2 Net Income
-$19.70 mln
Q2 Gross Margin
78.0%
Q2 Adjusted Gross Margin
83.0%


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 12 "strong buy" or "buy", 2 "hold" and 1 "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for Glaukos Corp is $120.00, about 21.9% above its July 29 closing price of $93.76

Press Release: ID:nBw6x4Xmpa

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)